Top 10 skin disorder stories of 2024
Click Here to Manage Email Alerts
Key takeaways:
- This year’s top story was about a phone screen protector triggering allergic contact dermatitis.
- Climate change, maternal diet and drug use all showed an impact on skin disorders.
The year 2024 was important for skin disorders with many innovations and breakthroughs.
The most-read Healio stories on the topic included an article on finding the link between asthma and atopic dermatitis, as well as the impact that climate change and diet has on AD. Other stories focused on drug advancements and how AI can shape the future. Check out the list below for the most popular Healio skin disorder stories of 2024.
Cell phone screen protector triggers allergic contact dermatitis
A woman who used an acrylate screen protector on her cell phone developed a rash on her face and fingers, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. Mohammad A. Younus, MD, allergist and immunologist at Hackensack University Medical Center, discussed the case. Read more.
Risks for asthma increase with AD
Patients with AD experienced greater risks for asthma, asthma exacerbations and hospitalizations than those without AD, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Adults with AD had a 38% greater risk for developing asthma than adults without AD. Also, Benjamin Ungar, MD, shared his Perspective. Read more.
Vegetarian diets during pregnancy linked with less AD in children
Vegetarian diets during pregnancy were associated with reduced risks for AD among children, according to a study published in Pediatric Allergy and Immunology. Additionally, vegan diets during pregnancy were associated with slightly lower odds for AD in children vs. lacto-ovo diets. Read more.
Quality of life improves with dupilumab for patients with chronic spontaneous urticaria
Patients with chronic spontaneous urticaria experienced better quality of life with dupilumab compared with placebo, according to two posters presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting. Marcus Maurer, MD, PhD, executive director of the Institute of Allergology at Charité – Universitätsmedizin Berlin, discussed his findings. Read more.
KalVista Pharmaceuticals submits FDA application for sebetralstat
KalVista Pharmaceuticals Inc. submitted a new drug application to the FDA for the approval of sebetralstat for patients aged 12 years and older with hereditary angioedema (HAE). Sebetralstat is the first on-demand oral therapy that would be available to patients with HAE. Also, Douglas H. Jones, MD, shares his Perspective. Read more.
Climate change aggravates AD
Climatic hazards associated with greenhouse gas emissions may exacerbate AD, including severity and flares, while increasing its prevalence and related health care utilization, according to a review published in Allergy. Katrina Abuabara, MD, MA, MSCE, associate professor of dermatology, University of California, discussed the results. Read more.
Barzolvolimab achieves complete responses in chronic inducible urticaria
Patients with cold urticaria and symptomatic dermographism experienced clinically meaningful and statistically significant complete responses with barzolvolimab, according to a webinar by Celldex Therapeutics. Diane C. Young, MD, senior vice president and chief medical officer at Celldex, and Anthony S. Marucci, MBA, MHL, founder, president, CEO and director of Celldex, shared comments about the topic. Read more.
Deep quantum modeling enables new drugs for HAE
With deep quantum modeling, researchers can go beyond the millions of distinct chemical structures previously accessible to scientists and explore 1060 possible combinations to find treatments for HAE and other diseases. Adityo Prakash, CEO of Verseon, spoke with Healio about using quantum physics to develop drugs for HAE and other diseases. Read more.
Baricitinib, dupilumab see comparable real-world results in AD
Responses to baricitinib and dupilumab were notable and similar among patients with moderate to severe AD in a real-world setting, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Reductions in Eczema Area and Severity Index scores were rapid and significant. Raj Chovatiya, MD, PhD, gave his Perspective. Read more.
Prenatal opioid exposure associated with eczema, dermatitis, asthma
Children who were exposed to opioids prenatally faced greater risks for infection, eczema and dermatitis, and asthma, but not for allergies, anaphylaxis or autoimmune diseases, according to a study published in JAMA Network Open. Erin Kelty, PhD, research fellow, School of Population and Global Health, University of Western Australia, discussed her findings. Read more.